Prelude Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-125,029
| Closed | -$8.51M | – | 1938 |
|
|
2022
Q3 | $8.51M | Buy |
+125,029
| New | +$6.9M | 0.31% | 46 |
|
|
2020
Q4 | – | Sell |
-7,705
| Closed | -$425K | – | 2194 |
|
|
2020
Q3 | $425K | Buy |
7,705
+1,855
| +32% | +$118K | 0.02% | 476 |
|
|
2020
Q2 | $369K | Buy |
+5,850
| New | +$401K | 0.02% | 561 |
|
|
2020
Q1 | – | Sell |
-138
| Closed | -$11K | – | 2205 |
|
|
2019
Q4 | $11K | Buy |
138
+15
| +12% | +$889 | ﹤0.01% | 1694 |
|
|
2019
Q3 | $6K | Sell |
123
-18,033
| -99% | -$940K | ﹤0.01% | 1557 |
|
|
2019
Q2 | $955K | Buy |
18,156
+7,708
| +74% | +$443K | 0.05% | 353 |
|
|
2019
Q1 | $553K | Buy |
+10,448
| New | +$513K | 0.03% | 473 |
|
|
2018
Q4 | – | Sell |
-57,446
| Closed | -$2.18M | – | 2280 |
|
|
2018
Q3 | $2.18M | Buy |
57,446
+8,283
| +17% | +$367K | 0.13% | 170 |
|
|
2018
Q2 | $2.22M | Buy |
49,163
+20,784
| +73% | +$946K | 0.14% | 129 |
|
|
2018
Q1 | $1.37M | Buy |
28,379
+26,183
| +1,192% | +$1.46M | 0.1% | 205 |
|
|
2017
Q4 | $86K | Sell |
2,196
-5,397
| -71% | -$202K | 0.01% | 821 |
|
|
2017
Q3 | $236K | Buy |
7,593
+2,593
| +52% | +$72.9K | 0.02% | 589 |
|
|
2017
Q2 | $137K | Buy |
5,000
+800
| +19% | +$23.8K | 0.01% | 697 |
|
|
2017
Q1 | $155K | Sell |
4,200
-300
| -7% | -$7.56K | 0.01% | 648 |
|
|
2016
Q4 | $65K | Sell |
4,500
-1,700
| -27% | -$29.9K | 0.01% | 975 |
|
|
2016
Q3 | $143K | Buy |
+6,200
| New | +$118K | 0.02% | 680 |
|
Other funds holding GBT
Prelude Capital Management's GBT Position: Q4 2022 in Review
Prelude Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 125,029 shares — an estimated $8.51M sold.
Prelude Capital Management first reported a position in GBT in Q3 2016 and held it in 16 quarters. The position peaked at $8.51M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Prelude Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Prelude Capital Management sold 125,029 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.51M.
- Prelude Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 16 quarters.
- Prelude Capital Management's Global Blood Therapeutics, Inc. position peaked at $8.51M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.